Page last updated: 2024-12-08

cyanotriphenylborate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cyanotriphenylborate: glycine receptor antagonist and chloride channel antagonist; structure given in first source; RN refers to sodium salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID23665403
CHEBI ID34659
SCHEMBL ID2769209
MeSH IDM0236407

Synonyms (17)

Synonym
14568-16-2
cyanotriphenylborate
sodium cyanotriphenylborate(1-)
sodium cyanotriphenylboranuide
sodium cyanotriphenylborate
sodium (cyano-c)triphenylborate(1-)
sodium (cyano-kappac)(triphenyl)borate(1-)
cesignost
CHEBI:34659
sodium (cyanido-kappac)(triphenyl)borate(1-)
SCHEMBL2769209
natriumtriphenylcyanoborat
QNLQNWKYDWFECJ-UHFFFAOYSA-N
DTXSID90932669
Q27116205
sodium;cyano(triphenyl)boranuide
sodium cyanotriphenylborate hydrate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organic sodium salt
tetraorganoborate saltCompounds with the general structure R4B(-)M(+), where R are organyl groups and M(+) is a metal cation.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]